Localization of TEIF in the centrosome and its functional association with centrosome amplification in DNA damage, telomere dysfunction and human cancers

Gong, Yanfen; Sun, Yue; McNutt, Michael A.; Sun, Qianqian; Hou, Lin; Liu, H; Shen, Qi; Ling, Yun; Chi, Yue; Zhang, B

doi:10.1038/onc.2008.503

Cited by 13 publications

(13 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to earlier reports in colorectal adenoma and CRC 109, TEIF positively correlates with CA in soft tissue sarcomas, and is related to tumour grade 166. In addition, in vitro overexpression of TEIF levels either exogenously introduced, or evoked by DNA-damaging agents or telomeric dysfunction promotes multinucleation, CA, mitotic defects, and chromosome missegregation 166.…”

Section: Centrosome Amplification In Solid Tumourssupporting

confidence: 86%

“…Numerical CA is more frequently observed in highly aggressive types of sarcomas, including PNET, synovial sarcoma, rhabdomyosarcoma, MFH, as compared to moderate grade sarcomas such as liposarcoma and leiomyosarcoma 166. The degree of CA is also significantly higher in recurrent and malignant cases than in non-recurrent cases of giant cell tumour of bone 167, in which a positive correlation exists between aneuploidy and CA.…”

Section: Centrosome Amplification In Solid Tumoursmentioning

confidence: 97%

“…In addition, in vitro overexpression of TEIF levels either exogenously introduced, or evoked by DNA-damaging agents or telomeric dysfunction promotes multinucleation, CA, mitotic defects, and chromosome missegregation 166. Collectively, this suggests that DNA damage evokes TEIF centrosomal expression, resulting in CA and genomic instability that contributes to tumour progression.…”

Section: Centrosome Amplification In Solid Tumoursmentioning

confidence: 98%

“…The degree of CA is also significantly higher in recurrent and malignant cases than in non-recurrent cases of giant cell tumour of bone 167, in which a positive correlation exists between aneuploidy and CA. Interestingly, benign or tumour-like lesions of soft tissue may also feature CA, albeit at lower frequencies 164-166.…”

Section: Centrosome Amplification In Solid Tumoursmentioning

confidence: 99%

See 3 more Smart Citations

A Clinical Overview of Centrosome Amplification in Human Cancers

Chan¹

2011

Int. J. Biol. Sci.

334

349

View full text Add to dashboard Cite

The turn of the 21st century had witnessed a surge of interest in the centrosome and its causal relation to human cancer development - a postulate that has existed for almost a century. Centrosome amplification (CA) is frequently detected in a growing list of human cancers, both solid and haematological, and is a candidate "hallmark" of cancer cells. Several lines of evidence support the progressive involvement of CA in the transition from early to advanced stages of carcinogenesis, being also found in pre-neoplastic lesions and even in histopathologically-normal tissue. CA constitutes the major mechanism leading to chromosomal instability and aneuploidy, via the formation of multipolar spindles and chromosomal missegregation. Clinically, CA may translate to a greater risk for initiation of malignant transformation, tumour progression, chemoresistance and ultimately, poor patient prognosis. As mechanisms underlying CA are progressively being unravelled, the centrosome has emerged as a novel candidate target for cancer treatment. This Review summarizes mainly the clinical studies performed to date focusing on the mechanisms underlying CA in human neoplasia, and highlights the potential utility of centrosomes in the diagnosis, prognosis and treatment of human cancers.

show abstract

Section: Centrosome Amplification In Solid Tumourssupporting

confidence: 86%

Section: Centrosome Amplification In Solid Tumoursmentioning

confidence: 97%

Section: Centrosome Amplification In Solid Tumoursmentioning

confidence: 98%

Section: Centrosome Amplification In Solid Tumoursmentioning

confidence: 99%

See 2 more Smart Citations

A Clinical Overview of Centrosome Amplification in Human Cancers

Chan¹

2011

Int. J. Biol. Sci.

334

349

View full text Add to dashboard Cite

show abstract

“…Overexpression and depletion of TEIF significantly affected centrosome status and increased mitotic abnormalities in a variety of cancer cell lines. Localization of TEIF to the centrosome was also increased by treatment with genotoxic agents and experimental telomere dysfunction, which concomitantly induced CA [95] . Thus, TEIF may be a factor linking CA and telomere dysfunction in CRC development.…”

Section: Introductionmentioning

confidence: 99%

The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancers

2016

View full text Add to dashboard Cite

Colon cancer is currently the third most common cancer and second most fatal cancer in the United States, resulting in approximately 600,000 deaths annually. Though colorectal cancer death rates are decreasing by about 3% every year, disease outcomes could be substantially improved with more research into the drivers of colon carcinogenesis, the determinants of aggressiveness in colorectal cancer and the identification of biomarkers that could enable choice of more optimal treatments. Colon carcinogenesis is notably a slow process that can take decades. Known factors that contribute to the development of colon cancer are mutational, epigenetic and environmental, and risk factors include age, history of polyps and family history of colon cancer. Colorectal cancers exhibit heterogeneity in their features and are often characterized by the presence of chromosomal instability, microscopic satellite instability, or CpG island methylator phenotype. In this review, we propose that centrosome amplification may be a widespread occurrence in colorectal cancers and could potently influence tumor biology. Moreover, the quantitation of this cancer-specific anomaly could offer valuable prognostic information and pave the way for further customization of treatment based on the organellar profile of patients. Patient stratification models that take into account centrosomal status could thus potentially reduce adverse side effects and result in improved outcomes for colorectal cancer patients.

show abstract

The Role of Centrosomes in Multiple Myeloma

Yan

Chng

2012

The Centrosome

View full text Add to dashboard Cite

Localization of TEIF in the centrosome and its functional association with centrosome amplification in DNA damage, telomere dysfunction and human cancers

Cited by 13 publications

References 47 publications

A Clinical Overview of Centrosome Amplification in Human Cancers

A Clinical Overview of Centrosome Amplification in Human Cancers

The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancers

The Role of Centrosomes in Multiple Myeloma

Contact Info

Product

Resources

About